PDS Biotechnology Corp
PDSB1.100USD
+0.010+0.92%
시장 운영 시간 （ET）시세는 15분 지연됩니다
49.99M시가총액
손실P/E TTM
자세한 내용은 PDS Biotechnology Corp 회사
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
회사 정보
종목 코드 PDSB
회사 이름PDS Biotechnology Corp
상장일Oct 01, 2015
CEODr. Frank Bedu-Addo, Ph.D.
직원 수24
유형Ordinary Share
회계 연도 종료Oct 01
주소303A College Road East
도시PRINCETON
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호08540
전화18002083343
웹사이트https://www.pdsbiotech.com
종목 코드 PDSB
상장일Oct 01, 2015
CEODr. Frank Bedu-Addo, Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
IR Contact Officer
IR Contact Officer
--
--
Mr. Spencer Brown
Mr. Spencer Brown
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. Stephan Toutain
Mr. Stephan Toutain
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Kirk V. Shepard, M.D.
Dr. Kirk V. Shepard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
IR Contact Officer
IR Contact Officer
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, Jul 26
마지막 업데이트: Sat, Jul 26
주주
주주 유형
주주
주주
비율
Armistice Capital LLC
9.67%
The Vanguard Group, Inc.
3.30%
Bedu-Addo (Frank)
1.51%
BlackRock Institutional Trust Company, N.A.
1.05%
Sykes (Richard)
0.97%
Other
83.49%
주주
주주
비율
Armistice Capital LLC
9.67%
The Vanguard Group, Inc.
3.30%
Bedu-Addo (Frank)
1.51%
BlackRock Institutional Trust Company, N.A.
1.05%
Sykes (Richard)
0.97%
Other
83.49%
주주 유형
주주
비율
Hedge Fund
9.80%
Investment Advisor
6.01%
Individual Investor
3.09%
Investment Advisor/Hedge Fund
1.54%
Research Firm
0.71%
Pension Fund
0.04%
Bank and Trust
0.01%
Other
78.80%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
187
9.67M
21.15%
+1.28M
2025Q1
201
9.77M
22.08%
+1.54M
2024Q4
205
5.67M
12.73%
-3.40M
2024Q3
205
5.76M
15.58%
-3.85M
2024Q2
208
6.94M
18.83%
-4.50M
2024Q1
195
8.96M
25.12%
-3.13M
2023Q4
194
9.68M
31.15%
-1.91M
2023Q3
192
9.20M
29.70%
-3.29M
2023Q2
183
9.26M
30.03%
-1.73M
2023Q1
149
11.76M
39.00%
-275.25K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Armistice Capital LLC
4.42M
9.67%
+4.42M
--
Mar 31, 2025
The Vanguard Group, Inc.
1.51M
3.3%
+4.41K
+0.29%
Mar 31, 2025
Bedu-Addo (Frank)
690.87K
1.51%
--
--
Apr 17, 2025
BlackRock Institutional Trust Company, N.A.
480.97K
1.05%
-4.48K
-0.92%
Mar 31, 2025
Sykes (Richard)
445.11K
0.97%
--
--
Apr 17, 2025
Geode Capital Management, L.L.C.
437.88K
0.96%
+20.66K
+4.95%
Mar 31, 2025
William Blair & Company, L.L.C. (Research)
257.20K
0.56%
+99.70K
+63.30%
Mar 31, 2025
UBS Financial Services, Inc.
245.33K
0.54%
+221.67K
+936.97%
Mar 31, 2025
State Street Global Advisors (US)
133.33K
0.29%
--
--
Mar 31, 2025
Conn (Gregory L Ph.D.)
123.59K
0.27%
--
--
Apr 17, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
iShares Micro-Cap ETF
0.01%
DFA Dimensional US Core Equity Market ETF
0%
Global X Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 Covered Call ETF
0%
더 보기
iShares Micro-Cap ETF
비율0.01%
DFA Dimensional US Core Equity Market ETF
비율0%
Global X Russell 2000 ETF
비율0%
Avantis US Small Cap Equity ETF
비율0%
Proshares Ultra Russell 2000
비율0%
ProShares Hedge Replication ETF
비율0%
iShares Russell 2000 Growth ETF
비율0%
iShares Russell 2000 ETF
비율0%
ProShares UltraPro Russell2000
비율0%
Global X Russell 2000 Covered Call ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
